HENDERSON, NV / ACCESSWIRE / June 2, 2016 / Rainbow Coral Corp. (OTCQB: RBCC) continues to seek new opportunities and breakthroughs in personalized medicine and recent news from Singapore could offer the company the ground floor chance it has been looking for to become a leader in this rapidly growing field.
Scientists in the southeast Asian nation have announced they have invented a means to 3D print medications customized to suit individual patients' unique needs. These tablets release drugs at specific (or personalized) timetables, or profiles, geared to the patient. The scientists, working at the National University of Singapore, say manufacturing the personalized pills via 3D printing is simple, versatile and inexpensive.
RBCC CEO Kimberly Palmer said, "This latest breakthrough in personalized medicine could lead to much more effective treatments and better overall health."
"This is an exciting breakthrough, both for medicine and for a company like ours," she said.
"With timed-release pills like these," Palmer explained, "those patients who tend to forget to take their medications can now get the full benefit of their prescriptions. This painlessly and easily solves the longstanding problem of patient compliance. For RBCC, this could be the opportunity we've been looking for to become a leader in the field. We'll be examining how to get into the manufacture of such pills and will be seeking potential partners also interested in this revolutionary process."
According to one published report, the personalized medicine market is expected to top $88 billion by 2022. 3D printing is a booming market on its own, with analysts predicting that industry will surpass $20 billion by 2020.
For more information on RBCC's initiatives, please visit www.rainbowbiocorp.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.rainbowbiocorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO
[email protected]
SOURCE: Rainbow Coral Corp.